Stock Market Reviews

CDXS (Codexis, Inc.) News

Get the latest news, insights, and market updates on CDXS (Codexis, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Codexis Reports Third Quarter 2025 Financial Results
  Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update th
  Nov 6, 2025 - $CDXS
• Codexis: Q3 Earnings Snapshot
  REDWOOD CITY, Calif. AP) — Codexis Inc. CDXS) on Thursday reported a loss of $19.6 million in its third quarter.
  Nov 6, 2025 - $CDXS
• EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
  EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.39% and -85.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $CDXS
• Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates
  Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +14.29% and +2.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $CDXS
• Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
  Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development and manufacturing organization (CDMO) specializing in oligonucleotide therapeutics, today announced that they have entered into an evaluation agreement.
  Oct 29, 2025 - $CDXS
• Codexis to Report Third Quarter 2025 Financial Results on November 6
  REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business upd
  Oct 23, 2025 - $CDXS
• Investors in Codexis (NASDAQ:CDXS) have unfortunately lost 79% over the last five years
  Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...
  Sep 25, 2025 - $CDXS
• Codexis to Participate in Cantor Global Healthcare Conference
  REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 3-5, 2025, in New York, New York. Management will participate in a fireside chat on Thursday, September 4, 2025, at 3:55 pm ET. A live webcast of the event will be available in the Investor Relations
  Aug 28, 2025 - $CDXS
• Codexis Second Quarter 2025 Earnings: Beats Expectations
  Codexis ( NASDAQ:CDXS ) Second Quarter 2025 Results Key Financial Results Revenue: US$15.3m (up 92% from 2Q 2024). Net...
  Aug 15, 2025 - $CDXS
• Codexis Inc (CDXS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Initiatives
  Codexis Inc (CDXS) reports a significant revenue increase and improved margins, while navigating challenges in meeting growing demand for its ECO platform.
  Aug 14, 2025 - $CDXS